Nano4Rare

Nano4Rare is a European project financed by the European Innovation Council and the SMEs Executive Agency. It has a singular focus: to bring a new nanopharmaceutical product for the treatment of Fabry disease (named as nanoGLA) to First-in Human clinical trials. NanoGLA is patent protected and was designated as Orphan Medicinal Product by the EMA in 2021, two important milestones with high implications for the translation of the new therapeutic product from bench to bedside. Nano4Rare project is expected to mature the development of this innovative nanopharmaceutical product by completing the GLP preclinical phase and regulatory approval. To achieve this objective, we will account with the collaboration of Nanomol Technologies SL, Leanbio-Pro SL, and MyBiotech GmbH, which are partners of its linked project 953110 PHOENIX that will cover the Chemistry, Manufacturing, and Controls (CMC) development. Additionally, in the frame of Nano4Rare, an appropriate business strategy will be implemented to ensure the financing of further clinical trials and the arrival to the market. #Horizon funded project under GA no. 101136772 🇪🇺